Clarus Ventures’s Astria Therapeutics ATXS Stock Holding History

Clarus Ventures’s Portfolio ATXS Stock Details ATXS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	$1.61M	Hold	33,470	–	–	0.38%	10
2018 Q2	$1.93M	Hold	33,470	–	–	0.68%	8
2018 Q1	$3.63M	Sell	33,470 -12,405	-27%	-$1.24M	3.72%	6
2017 Q4	$4.1M	Hold	45,875	–	–	4.08%	5
2017 Q3	$5.83M	Hold	45,875	–	–	4.75%	4
2017 Q2	$3.88M	Hold	45,875	–	–	3.57%	4
2017 Q1	$4.4M	Hold	45,875	–	–	3.28%	6
2016 Q4	$9.94M	Hold	45,875	–	–	6.55%	4
2016 Q3	$17M	Hold	45,875	–	–	10.42%	4
2016 Q2	$10.2M	Hold	45,875	–	–	8.91%	5
2016 Q1	$13.9M	Hold	45,875	–	–	10.42%	4
2015 Q4	$21.8M	Hold	45,875	–	–	15.3%	3
2015 Q3	$22.3M	Hold	45,875	–	–	12.81%	4
2015 Q2	$33.6M	Buy	+45,875	New	+$34.7M	14.78%	3

Other funds holding ATXS

Federated Hermes

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

SV Health Investors Boston, Massachusetts $32.3M AUM 20.15% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Stonepine Capital Management Bend, Oregon $114M AUM 77.6% 1-Year Est. Return

CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return

Oppenheimer & Co New York $8.21B AUM 28.81% 1-Year Est. Return

Renaissance Technologies

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return